ALFA Finder| Revenue growth | Revenue up 18.3% YoY, split across US and LatAm. |
|---|---|
| Margins | EBITDA 38.7% in H1; Q2 softer q/q, management calls it timing. |
| Demand visibility | CSU daily sales doubled to $61k; LatAm growth softer per analyst. |
| Management confidence | Confident but defensive on US margin and cash deployment questions. |
Growth
Revenue up 18.3% YoY across US and LatAm. Q2 margins fell q/q as B2B milestone income declines.
Outlook
US revenue guided 20-25% growth in FY27 despite line downtime. C OL2 completion by August 2027. CRO beds to 120 by FY-end.
Risks
FDA classification for Gumuri facility pending. Freight-driven cost rise, US line downtime, and C OL2 completion slip risk.
Earnings Call Transcript filed with NSE, NSE: CAPLIPOINT. Summary written with AI assistance from the document.
Caplin Point Laboratories Ltd: key numbers
- Share price
- ₹2,388.70
- Market cap
- ₹18,157 Cr
- Revenue (annual)
- ₹2,187 Cr
- Net profit (annual)
- ₹641.2 Cr
- P/E (TTM)
- 26.4×Sector 43.7×
- Promoter holding
- 70.57%+0.00% QoQ
- FII holding
- 5.72%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Caplin Point Laboratories Ltd
All →Caplin Point Laboratories Q2 FY27 Results: Net Profit ₹182.3 Cr, Up 13.8% YoY
Caplin Point Laboratories Ltd reported revenue from operations of ₹629.8 Cr (+17.9% YoY) and net profit of ₹182.3 Cr (+13.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹182.3 Cr · +13.8% YoY
Caplin Point Laboratories Board Meeting Date
Caplin Point schedules a 12 November 2026 board meeting for unaudited quarterly and half-year results. The trading window stays closed until 14 November 2026.
Caplin Point Laboratories Other Announcement
Caplin Point Laboratories Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI listing regulations.
Caplin Point Laboratories Annual General Meeting
Caplin Point Laboratories concluded its 35th Annual General Meeting on September 25, 2026. Key business included adopting financial statements and approving the final dividend declaration.
Caplin Point Laboratories Price Movement Clarification
Caplin Point Laboratories clarified that the recent increase in its stock's trading volume is market-driven. The company confirmed no undisclosed material information exists regarding this movement.
Caplin Point Laboratories Other Announcement
Caplin Point Laboratories Limited shared a weblink for its 35th AGM Notice and Annual Report for FY 2025-26. The communication targets shareholders with unregistered email addresses.